Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 1, 2004, Pages 38-44

  Sparreboom, Alex ^a   Gelderblom, Hans ^b   Marsh, Sharon ^b   Ahluwalia, Ranjeet ^b   Obach, Rosendo ^b   Principe, Paola ^b   Twelves, Chris ^b   Verweij, Jaap ^b   McLeod, Howard L ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIFLOMOTECAN; DNA TOPOISOMERASE INHIBITOR;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTESTINE; LIVER; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ALLELES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS;

EID: 3042651340     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.03.003     Document Type: Article

References (37)

1. Bates S.E., Robey R., Miyake K., Rao K., Ross D.D., Litman T. The role of half-transporters in multidrug resistance. J Bioenerg Biomembr. 33:2001;503-511
2. Leonard G.D., Polgar O., Bates S.E. ABC transporters and inhibitors new targets, new agents. Curr Opin Investig Drugs. 3:2002;1652-1659
3. Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58:1998;5337-5339
4. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 95:1998;15665-15670
5. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells demonstration of homology to ABC transport genes. Cancer Res. 59:1999;8-13
6. Allen J.D., Schinkel A.H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther. 1:2002;427-434
7. Ross D.D., Yang W., Abruzzo L.V., Dalton W.S., Schneider E., Lage H., et al. Atypical multidrug resistance breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst. 91:1999;429-433
8. Brangi M., Litman T., Ciotti M., Nishiyama K., Kohlhagen G., Takimoto C., et al. Camptothecin resistance role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 59:1999;5938-5946
9. Miyake K., Litman T., Robey R., Bates S.E., Brangi M. Camptothecin resistance role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Lett. 146:1999;117-126
10. Chen Z.S., Robey R.W., Belinsky M.G., Shchaveleva I., Ren X.Q., Sugimoto Y., et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2 effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 63:2003;4048-4054
11. Volk E.L., Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 63:2003;5538-5543
12. Rajendra R., Gounder M.K., Saleem A., Schellens J.H., Ross D.D., Bates S.E., et al. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res. 63:2003;3228-3233
13. Nakatomi K., Yoshikawa M., Oka M., Ikegami Y., Hayasaka S., Sano K., et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 288:2001;827-832
14. Maliepaard M., van Gastelen M.A., de Jong L.A., Pluim D., van Waardenburg R.C., Ruevekamp-Helmers M.C., et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 59:1999;4559-4563
15. Bates S.E., Medina-Perez W., Kohlhagen G., Pommier Y. BCRP/MXR/ABCG2-mediated resistance to homocamptothecins [abstract]. Proc Am Assoc Cancer Res. 44:2003;113
16. Rocchi E., Khodjakov A., Volk E.L., Yang C.H., Litman T., Bates S.E., et al. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun. 271:2000;42-46
17. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61:2001;3458-3464
18. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst. 92:2000;1651-1656
19. Jonker J.W., Buitelaar M., Wagenaar E., Van Der Valk M.A., Scheffer G.L., Scheper R.J., et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A. 99:2002;15649-15654
20. Iida A., Saito S., Sekine A., Mishima C., Kitamura Y., Kondo K., et al. Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet. 47:2002;285-310
21. Imai Y., Nakane M., Kage K., Tsukahara S., Ishikawa E., Tsuruo T., et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther. 1:2002;611-616
22. Zamber C.P., Lamba J.K., Yasuda K., Farnum J., Thummel K., Schuetz J.D., et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics. 13:2003;19-28
23. Lockhart A.C., Tirona R.G., Kim R.B. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2:2003;685-698
24. Allen J.D., Jackson S.C., Schinkel A.H. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res. 62:2002;2294-2299
25. Honjo Y., Hrycyna C.A., Yan Q.W., Medina-Perez W.Y., Robey R.W., van de Laar A., et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61:2001;6635-6639
26. Gelderblom H., Salazar R., Verweij J., Pentheroudakis G., de Jonge M.J., Devlin M., et al. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res. 9:2003;4101-4107
27. Rose C.M., Marsh S., Ameyaw M.M., McLeod H.L. Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Methods Mol Med. 85:2003;225-237
28. Mathijssen R.H.J., Marsh S., Karlsson M.O., Xie R., Baker S.D., Verweij J., et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res. 9:2003;3251-3258
29. Hesselink D.A., van Schaik R.H., van der Heiden I.P., van der Werf M., Gregoor P.J., Lindemans J., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 74:2003;245-254
30. DeMario M.D., Ratain M.J. Oral chemotherapy rationale and future directions. J Clin Oncol. 16:1998;2557-2567
31. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 97:2000;3473-3478
32. Sparreboom A., Danesi R., Ando Y., Chan J., Figg W.D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat. 6:2003;71-84
33. Eiselt R., Domanski T.L., Zibat A., Mueller R., Presecan-Siedel E., Hustert E., et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics. 11:2001;447-458
34. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 27:2001;383-391
35. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 54:2002;1271-1294
36. Hustert E., Haberl M., Burk O., Wolbold R., He Y.Q., Klein K., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 11:2001;773-779
37. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 70:2001;189-199